Drug development

…Sessions also address drug development, regulatory decisions, artificial intelligence and the sustainability of pharmacological research. Plenary lectures connect unmet needs in oncology to improved care and

…across molecular biology, genetics, drug development and related neuroscience. A live virtual core programme links local hubs in Bangkok, Cairo, Ljubljana and Nicosia, with mentoring, networking and career-development opportunities. All participants complete the global registration; those attending physically also complete a separate registration for their chosen hub.

…to neuroscience, biological aging and drug development.

…structure and causality, failures in drug development and the limits of speeding up wet-lab work with AI agents. It also considers foundation models for biology, generalization beyond observed data, human evidence and scientific discovery. Hosted by Ravid Shwartz Ziv and Allen Roush. Watch the full conversation on the publisher’s YouTube channel.

The World Health Organization (WHO) estimates that untreated mental disorders accountfor 13% of the total global burden of disease, and by 2030, depression alone will be the leadingcause of disability around the world – outpacing heart disease, cancer, and HIV. This grim pictureis further compounded by the mental health burden delivered by the coronavirus pandemic.The lack of novel treatment options in psychiatry is restricted by a limited understanding in theneuroscience basis of mental disorders, availability of relevant biomarkers, poor predictability inanimal models, and high failure rates